5424-16-8

Usage

Uses

Used in Pharmaceutical Research:
3-Alpha-Aminotropane Dihydrochloride is used as a research compound for studying its effects on neurotransmitter release and its potential role in treating mood disorders and attention deficit hyperactivity disorder (ADHD). Its mechanism of action involves the release of dopamine, norepinephrine, and serotonin in the brain, which may contribute to its stimulant and euphoric effects.
Used in Neurotransmitter Release Studies:
In the field of neuroscience, 3-Alpha-Aminotropane Dihydrochloride is used as a tool to investigate the release of neurotransmitters, such as dopamine, norepinephrine, and serotonin. Understanding its effects on neurotransmitter release can provide insights into the development of new treatments for mood disorders and ADHD.
Used in Substance Abuse Research:
Due to its potential for abuse and addiction, 3-Alpha-Aminotropane Dihydrochloride is used in research aimed at understanding the mechanisms of substance abuse and addiction. Studying its effects on the brain can help in the development of strategies to prevent and treat addiction.
Used in Toxicology Studies:
3-Alpha-Aminotropane Dihydrochloride is used in toxicology research to investigate its adverse effects, such as cardiovascular issues and neurotoxicity. Understanding these effects is crucial for assessing the risks associated with its use and for developing potential countermeasures or treatments for its toxic effects.

Upstream product

• 532-24-1 tropinone 
• 87571-88-8 3-endo-tropanamine 
• 56620-28-1 (5S)-8-methyl-8-azabicyclo[3.2.1]octan-2-one 
• 532-24-1 tropinone 

Downstream Products

• 806648-84-0 tropane-3exo-yl-carbamic acid ethyl ester 
• 1609071-00-2 5-chloro-1-cyclopropyl-6,7-bis((4-methoxybenzyl)oxy)-N-((1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]octane-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 1609071-86-4 C₃₂H₃₄N₂O₆ 
• 1617538-52-9 4-chloro-N-[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]benzamide 
• 1609071-60-4 C₃₂H₃₅ClN₂O₆ 

Relevant academic research and scientific papers

Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders

The development of medications to treat cocaine use disorders has thus far defied success, leaving this patient population without pharmacotherapeutic options. As the dopamine transporter (DAT) plays a prominent role in the reinforcing effects of cocaine that can lead to addiction, atypical DAT inhibitors have been developed that prevent cocaine from binding to DAT, but they themselves are not cocaine-like. Herein, a series of novel DAT inhibitors were synthesized, and based on its pharmacological profile, the lead compound 10a was evaluated in phase I metabolic stability studies in mouse liver microsomes and compared to cocaine in locomotor activity and drug discrimination paradigms in mice. A molecular dynamic simulation study supported the hypothesis that atypical DAT inhibitors have similar binding poses at DAT in a conformation that differs from that of cocaine. Such differences may ultimately contribute to their unique behavioral profiles and potential for development as cocaine use disorder therapeutics.

1,4-DISUBSTITUTED 1,2,3-TRIAZOLES, METHODS FOR PREPARING SAME, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF

A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; orX is a carbon atom and Y is a nitrogen atom;the Ar group is an aryl or heteroaryl group; andthe RN and RN′ groups, together with the carbon atoms

A practical synthesis of 7-azaindolylcarboxy-endo-tropanamide (DF 1012)

An optimised cost-effective synthesis of the new antitussive drug, DF1012, is herewith reported. The new synthetic route to the key intermediate DF1005 is based on the unusual deprotection step of the 1-tert-butyl-3-cyano-7-azaindole intermediate, which can also be regarded as a convenient way for the industrial production of the expensive 7-azaindole 1. The second key intermediate, endo-tropanamine 6, was obtained in high yield by a novel one-pot stereoselective process using a Pd-catalysed reductive amination procedure.

A modified palladium catalysed reductive amination procedure

New, extended applications of a modified palladium catalysed reductive amination procedure are described; a mechanistic hypothesis alternative to the common imine pathway is proposed. This versatile method advances the usual reductive amination processes

Stereoselective process for making endo-tropanamine and like compounds

A stereoselective process for forming compounds related to 4-endotropanamine through the reactive amination of a corresponding ketone with a triacyloxy borohydride.